![Stefan Pflanz](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Stefan Pflanz
Direktor/Vorstandsmitglied bei
TigaTx, Inc.
Profil
Stefan Pflanz currently works at Boehringer Ingelheim (Venture Capital), as Executive Director from 2020, Bodyport, Inc., as Director, and TigaTx, Inc., as Director.
Aktive Positionen von Stefan Pflanz
| Unternehmen | Position | Beginn |
|---|---|---|
Boehringer Ingelheim (Venture Capital)
 Boehringer Ingelheim (Venture Capital) Investment ManagersFinance BIVF invests in companies located across the globe including the United States, Europe and China. The firm targets companies operating in groundbreaking innovation including cancer, regenerative medicine, auto-immunity indications, digital solutions and infectious disease. It participaotes in seed and early stage capital requirements. The firm acquires minority interest and makes follow-on investments. It also takes seat on the board of directors. | Private Equity Investor | 01.01.2020 |
Bodyport, Inc.
 Bodyport, Inc. Packaged SoftwareTechnology Services Publishes mobile applications which provides blood pressure, heart rate and other health information | Direktor/Vorstandsmitglied | - |
TigaTx, Inc.
 TigaTx, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops engineered immunoglobulin to create isotype cancer antibody | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
41
Beziehungen ersten Grades
3
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Boehringer Ingelheim (Venture Capital)
Boehringer Ingelheim (Venture Capital) Investment ManagersFinance BIVF invests in companies located across the globe including the United States, Europe and China. The firm targets companies operating in groundbreaking innovation including cancer, regenerative medicine, auto-immunity indications, digital solutions and infectious disease. It participaotes in seed and early stage capital requirements. The firm acquires minority interest and makes follow-on investments. It also takes seat on the board of directors. | Finance |
Bodyport, Inc.
Bodyport, Inc. Packaged SoftwareTechnology Services Publishes mobile applications which provides blood pressure, heart rate and other health information | Technology Services |
TigaTx, Inc.
TigaTx, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops engineered immunoglobulin to create isotype cancer antibody | Health Technology |
